Trial reportPsychopharmacology2013
A standardized kudzu extract (NPI-031) reduces alcohol consumption in nontreatment-seeking male heavy drinkers.
Trial report in Psychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- A single dose of kudzu extract reduces alcohol consumption in a binge drinking paradigm.Drug and alcohol dependence · 2015Trial
- Effects of idazoxan on alcohol pharmacokinetics and intoxication: a preliminary human laboratory study.Alcoholism, clinical and experimental research · 2015Trial
- The isoflavone puerarin reduces alcohol intake in heavy drinkers: a pilot study.Drug and alcohol dependence · 2012Trial
- Effects of kudzu extract on alcohol consumption among men and women seeking treatment for alcohol use disorder.Drug and alcohol dependence reports · 2026Article
- Molecular Mechanistic Pathways Targeted by Natural Products in the Prevention and Treatment of Alcoholic Liver Disease.Life (Basel, Switzerland) · 2026Review
- Puerarin: a hepatoprotective drug from bench to bedside.Chinese medicine · 2024Review
- Medicinal plants used by traditional medicine practitioners in treatment of alcohol-related disorders in Bushenyi District, southwestern Uganda.Frontiers in pharmacology · 2024Article
- Can gene therapy be used to prevent cancer? Gene therapy for aldehyde dehydrogenase 2 deficiency.Cancer gene therapy · 2022Review
- Development of Kudzu (Pueraria Montana var. lobata) Reference Materials for the Determination of Isoflavones and Toxic Elements.Journal of AOAC International · 2022Article
- Differential Influence ofPharmaceuticals (Basel, Switzerland) · 2021Article
- Plants with Anti-Addictive Potential.Advances in experimental medicine and biology · 2021Article
- The Efficacy and Safety of Multiple Dose Regimens of Kudzu (Frontiers in pharmacology · 2021Article
- Methanolic extract of Mitragyna speciosa Korth leaf inhibits ethanol seeking behaviour in mice: involvement of antidopaminergic mechanism.Metabolic brain disease · 2019Article
- Applications ofChinese herbal medicines · 2019Article
- Ethnopharmacological Applications Targeting Alcohol Abuse: Overview and Outlook.Frontiers in pharmacology · 2019Review
- Soy Isoflavone Extract Does Not Increase the Intoxicating Effects of Acute Alcohol Ingestion in Human Volunteers.Frontiers in pharmacology · 2019Article
- Altering ethanol pharmacokinetics to treat alcohol use disorder: Can you teach an old dog new tricks?Journal of psychopharmacology (Oxford, England) · 2017Review
- Assessment of the Effects of 6 Standard Rodent Diets on Binge-Like and Voluntary Ethanol Consumption in Male C57BL/6J Mice.Alcoholism, clinical and experimental research · 2015Article
- Analysis of γ-aminobutyric acid (GABA) type A receptor subtypes using isosteric and allosteric ligands.Neurochemical research · 2014Article
- Alcohol use disorder: pathophysiology, effects, and pharmacologic options for treatment.Substance abuse and rehabilitation · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveWe previously demonstrated that short-term treatment with a standardized kudzu extract (NPI-031) reduced alcohol drinking by men and women in a natural setting. The present study was conducted in nontreatment-seeking heavy drinkers to assess the safety and efficacy of 4 weeks of kudzu extract in an outpatient setting.
methodThis randomized between-subject, double-blind, placebo-controlled study involved 2 weeks of baseline, 4 weeks of treatment, and 2 weeks of follow-up. Seventeen men (21-33 years) who reported drinking 27.6 ± 6.5 drinks/week with a diagnosis of alcohol abuse/dependence took either kudzu extract (250 mg isoflavones, t.i.d.) or matched placebo on a daily basis. They reported alcohol consumption and desire to use alcohol using a wrist actigraphy device; twice weekly laboratory visits were scheduled to monitor medication adherence and adverse events.
resultsMedication adherence was excellent and there were no adverse events and changes in vital signs, blood chemistry, and renal or liver function. There was no effect on alcohol craving, but kudzu extract significantly reduced the number of drinks consumed each week by 34-57 %, reduced the number of heavy drinking days, and significantly increased the percent of days abstinent and the number of consecutive days of abstinence.
conclusionsA standardized formulation of kudzu extract produced minimal side effects, was well-tolerated, and resulted in a modest reduction in alcohol consumption in young nontreatment-seeking heavy drinkers. Additional studies using treatment-seeking alcohol-dependent persons will be necessary to determine the usefulness of this herbal preparation in reducing alcohol use in other populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.